Combination Potential of Cyclacel’s Sapacitabine and Seliciclib Reported at AACR

[at noodls] – Sequential Treatment Showed Antitumor Activity in Patients With Incurable BRCA-Deficient Cancers BERKELEY HEIGHTS, N.J., April 9, 2013 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) … more

View todays social media effects on CYCC

View the latest stocks trending across Twitter. Click to view dashboard

See who Cyclacel is hiring next, click here to view